Summary:
- The article advocates for the ethical and necessary inclusion of infants and young children in clinical trials to ensure that medical treatments and dosages are evidence-based and safe for pediatric populations.
- It highlights the historical "therapeutic orphan" problem, where children are often excluded from research, leading to a reliance on "off-label" prescribing that lacks rigorous scientific validation for younger physiology.